Table 3.
Factors affecting the subject Methylation dysregulation index.
| Agea |
Female vs. Male |
Early vs. late stageb |
Estimated tumor purity |
Fraction of genome alteredc |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| β (95% CI) | P-value | β (95% CI) | P-value | β (95% CI) | P-value | β (95% CI) | P-value | β (95% CI) | P-value | R2 | |
| BLCA | −0.26 (−0.05,0.002) | 0.06 | 0.32 (−0.35,0.99) | 0.35 | −0.73 (−1.37,−0.1) | 0.02 | 0.49 (0.03,0.07) | 3.30E-07 | 0.63 (0.05,0.08) | 2.70E-15 | 25.1% |
| BRCA | 0.38 (0.03,0.05) | 5.87E-10 | 1.66 (0.24,3.09) | 0.02 | −0.03 (−0.37,0.32) | 0.87 | 0.12 (0.004,0.02) | 3.84E-03 | 0.42 (0.03,0.05) | 5.77E-26 | 20.2% |
| COAD | 0.16 (−0.004,0.04) | 0.11 | −0.13 (−0.64,0.38) | 0.61 | −0.47 (−1.01,0.06) | 0.08 | 0.42 (0.02,0.06) | 6.46E-06 | 0.27 (0.01,0.04) | 7.12E-04 | 12.2% |
| ESCA | 0.01 (−0.03,0.03) | 0.93 | −0.46 (−1.41,0.5) | 0.35 | −0.11 (−0.81,0.58) | 0.75 | 0.21 (0.004,0.04) | 0.01 | 0.43 (0.02,0.06) | 1.56E-05 | 14.8% |
| HNSC | −0.02 (−0.02,0.02) | 0.83 | −0.06 (−0.53,0.41) | 0.79 | 0.56 (0.06,1.05) | 0.03 | 0.12 (−0.001,0.02) | 0.07 | 0.6 (0.05,0.07) | 1.72E-19 | 19.4% |
| KIRC | 0.06 (−0.01,0.02) | 0.30 | 0.13 (−0.17,0.43) | 0.39 | 0.69 (0.4,0.98) | 4.48E-06 | 0.003 (−0.01,0.01) | 0.96 | 0.32 (0.02,0.04) | 2.42E-10 | 20.7% |
| KIRP | 0.01 (−0.02,0.02) | 0.90 | −0.17 (−0.69,0.35) | 0.52 | 1.6 (1.07,2.12) | 7.14E-09 | 0.05 (−0.01,0.02) | 0.57 | 0.15 (0.003,0.03) | 0.01 | 18.3% |
| LIHC | 0.68 (0.04,0.1) | 3.60E-06 | 0.39 (−0.4,1.19) | 0.33 | 0.68 (−0.18,1.54) | 0.12 | 0.35 (0.01,0.06) | 0.01 | 0.71 (0.05,0.09) | 6.07E-11 | 18.8% |
| LUAD | 0.04 (−0.01,0.02) | 0.58 | 0.57 (0.26,0.89) | 4.21E-04 | −0.05 (−0.44,0.34) | 0.80 | 0.04 (−0.01,0.01) | 0.39 | 0.77 (0.07,0.09) | 1.17E-53 | 46.8% |
| LUSC | 0.08 (−0.03,0.04) | 0.63 | 0.35 (−0.32,1.02) | 0.30 | 0.21 (−0.58,1.01) | 0.60 | 0.2 (0.003,0.04) | 0.02 | 0.7 (0.06,0.08) | 7.77E-20 | 25.8% |
| PAAD | −0.03 (−0.02,0.02) | 0.79 | 0.59 (0.14,1.04) | 9.84E-03 | −0.13 (−1.09,0.83) | 0.79 | 0.003 (−0.01,0.01) | 0.94 | 0.95 (0.08,0.11) | 1.81E-32 | 58.9% |
| PRAD | 0.28 (0.001,0.06) | 0.04 | NA | NA | −0.11 (−0.5,0.28) | 0.58 | 0.35 (0.02,0.05) | 3.26E-10 | 1.1 (0.09,0.13) | 5.31E-26 | 34.1% |
| THCA | 0.09 (0.002,0.01) | 6.44E-03 | 0.2 (0.01,0.38) | 0.04 | 0.14 (−0.07,0.35) | 0.18 | 0.1 (0.01,0.02) | 9.08E-05 | 0.29 (0.02,0.04) | 3.77E-05 | 11.7% |
| UCEC | 0.07 (−0.01,0.03) | 0.51 | NA | NA | −0.22 (−0.68,0.24) | 0.35 | 0.26 (0.01,0.04) | 3.43E-04 | 0.02 (−0.01,0.01) | 0.60 | 3.8% |
a
per each 10 y increase,
b
Early (I+II), and late (III+IV),
c
per each 10% increase
Note: In bold those P-values ≤ 0.01 (Bonferroni correction for 5 comparisons).